Newsletter
Archive Press
Home
Company
APR Acquisition
Pipeline
Partnering
Investor Relations
News and Events
Contact
Privacy Policy
Disclaimer
Imprint
Archive Press
Archive Financial
© relief therapeutics 2021
Corporate News
All news
Ad Hoc Announcement Pursuant To Art. 53 LR
28 July 2021
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
28 July 2021
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita
26 July 2021
Relief Therapeutics Announces CHF 15 Million Private Placement
23 July 2021
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
22 July 2021
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
20 July 2021
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
13 July 2021
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
29 June 2021
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
21 June 2021
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
16 June 2021
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
02 June 2021
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
28 May 2021
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
27 May 2021
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
25 May 2021
Relief’s Partner Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
18 May 2021
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
17 May 2021
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
04 May 2021
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
22 April 2021
Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome
19 April 2021
Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.
15 April 2021
Relief Reports 2020 Financial Results and Provides Business Update
07 April 2021
Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant
07 April 2021
Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir
30 March 2021
Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100™ (aviptadil)
22 March 2021
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
15 March 2021
Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals
12 March 2021
Relief Announces CHF 10 Million Private Placement
08 March 2021
Relief Increases Issued Share Capital with Creation of Treasury Shares
24 February 2021
Relief Reports that NeuroRx Announced that RLF-100™ (Aviptadil) has Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28 Day Interim Endpoint
10 February 2021
Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100™ (aviptadil)
09 February 2021
Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors
08 February 2021
Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100™ (Aviptadil; ZYESAMI™) in Severe COVID-19 Patients
25 January 2021
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
21 January 2021
Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM
20 January 2021
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
11 January 2021
Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
30 December 2020
Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
21 December 2020
Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer
18 December 2020
Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority
07 December 2020
Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
25 November 2020
Correction: NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients
24 November 2020
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients
23 November 2020
Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG
18 November 2020
Relief Selects CRO and CDMO for RLF-100TM in Europe
13 November 2020
Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
05 November 2020
Relief Therapeutics and NeuroRx announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020
04 November 2020
Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team
13 October 2020
NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19
08 October 2020
Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
30 September 2020
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil)
28 September 2020
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM
23 September 2020
Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
21 September 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners
15 September 2020
Relief Reports Half-Year 2020 Results
04 September 2020
Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer
31 August 2020
Relief Announces Successful Up-listing from OTC Pink to OTCQB and Capital Increase from its Share Subscription Facility with GEM
20 August 2020
Relief Therapeutics and NeuroRx note submission of clinical results from 21 patient study for publication
06 August 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
03 August 2020
RLF-100 (aviptadil) clinical trial showe respiratory failure and inhibition of co human lung cells
29 July 2020
FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19
20 July 2020
RELIEF THERAPEUTICS Holding SA (SIX:RLF) shareholders approve all resolutions at its Ordinary General Meeting 2020 – Prof. Jonathan Javitt elected Vice Chairman of the Board of Directors
16 July 2020
NeuroRx and Relief Therapeutics announce Data Monitoring Committee determination to continue phase 2/3 trial of RLF-100 for Critical COVID-19
16 July 2020
RELIEF THERAPEUTICS Holding SA to agree share settlement for an outstanding CHF 1’723’300 debt position provided by GEM
16 July 2020
RELIEF THERAPEUTICS Holding SA to agree share settlement for an outstanding CHF 1’723’300 debt position provided by GEM
16 July 2020
RELIEF THERAPEUTICS Holding SA to agree share settlement for an outstanding CHF 1’723’300 debt position provided by GEM
24 June 2020
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
17 June 2020
RELIEF THERAPEUTICS Holding SA (SIX:RLF) announces the report of its Ordinary General Meeting 2020
16 June 2020
NeuroRx and Relief Therapeutics announce Data Monitoring Committee determination to continue phase 2/3 trial of RLF-100 for Critical COVID-19
11 June 2020
Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital
08 June 2020
Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to all patients with Critical COVID-19 and Respiratory Failure
02 June 2020
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
25 May 2020
Relief Therapeutics (RLF:SIX) drug Aviptadil enters FDA trial at University of Miami, to treat COVID-19-induced Respiratory Distress Aviptadil targets the cytokine storm that causes fatal Respiratory Distress in COVID-19
14 May 2020
Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
11 May 2020
Relief Therapeutics announces filing of IND for Phase 2/3 Clinical Trial of inhaled RLF-100 targeting early COVID-19 Lung Injury
06 May 2020
Relief Therapeutics Holding (RLF:SIX) drug Aviptadil enters FDA trial at NYU Langone Health, New York, to treat COVID-19-induced Acute Respiratory Distress
30 April 2020
RELIEF THERAPEUTICS Holding SA announces today the publication of its annual report for the year ended 2019 and provides corporate updates
09 April 2020
Relief Therapeutics (RLF:SIX) drug Aviptadil enters FDA trial at Thomas Jefferson University Hospital in Philadelphia, to treat COVID-19-induced Acute Respiratory Distress
02 April 2020
RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA
29 March 2020
FDA grants IND “Study May Proceed” for COVID-19 trial to NeuroRx, Inc. in partnership with RELIEF THERAPEUTICS (SIX:RLF) for treatment of Acute Respiratory Distress
25 March 2020
RELIEF THERAPEUTICS HOLDING SA (SIX:RLF) and NeuroRx, Inc. file FDA IND for Aviptadil to treat COVID-19-induced Respiratory Distress
17 March 2020
RELIEF THERAPEUTICS HOLDING SA (SIX: RLF) announces plans to test Aviptadil for the treatment of COVID-induced Acute Respiratory Distress Syndrome (ARDS). Compassionate care protocol to be conducted at Rambam Healthcare Campus in coordination with the Gov
11 March 2020
RELIEF THERAPEUTICS Holding SA (SIX: RLF) announces the proposal of Prof. Jonathan Javitt, M.D., M.P.H., at the upcoming general assembly as Vice Chairman of the Board
12 August 2019
RELIEF THERAPEUTICS Holding SA Announces Divestment of its Subsidiary Relief Therapeutics SA to Sonnet BioTherapeutics, Inc. to Ensure the Development of Atexakin Alpha (Interleukin-6)
02 August 2019
RELIEF THERAPEUTICS Holding SA announces termination of the agreements with Genclis and H&H Group
14 June 2019
RELIEF THERAPEUTICS Holding AG (SIX:RLF) announces today the results of its Annual General Meeting 2019
06 June 2019
RELIEF THERAPEUTICS Holding AG announces an increase of its capital consecutive to a draw down on its Share Subscription Facility
25 May 2019
RELIEF THERAPEUTICS Holding AG (SIX: RLF) announces significant change in its shareholding structure
24 May 2019
RELIEF THERAPEUTICS Holding AG (SIX: RLF) publishes the agenda for its 2019 Annual General Meeting
30 April 2019
RELIEF THERAPEUTICS Holding SA announces today the publication of its annual report for the year ended 2018
26 April 2019
RELIEF THERAPEUTICS Holding AG announces changes to its management structure
23 April 2019
RELIEF THERAPEUTICS Holding SA announces a Letter of Intent with ENTEROSYS SAS for the co-development of atexakin alfa towards novel indications
17 October 2018
RELIEF THERAPEUTICS Holding SA announces signature of service agreement with Genclis SA
18 September 2018
RELIEF THERAPEUTICS Holding SA announces the prolongation and raise of the amount from the Share Subscription Facility agreement with GEM
13 September 2018
RELIEF THERAPEUTICS Holding SA announces an out-licensing agreement with H&H Group
02 August 2018
RELIEF THERAPEUTICS Holding SA announces a formal commitment by GEM Global Yield Fund LLC SCS to amend and prolong the Share Subscription Facility (SSF) currently in effect
08 June 2018
RELIEF THERAPEUTICS Holding AG (SIX: RLF) publishes the agenda for its 2018 Annual General Meeting
02 June 2018
RELIEF THERAPEUTICS Holding AG (SIX:RLF) announces today the results of its Annual General Meeting 2018
23 April 2018
RELIEF THERAPEUTICS Holding SA announces that it has granted an option to license Aviptadil to Seren Clinical
09 April 2018
RELIEF THERAPEUTICS Holding SA announces an in-licensing agreement with Genclis SA
06 November 2017
RELIEF THERAPEUTICS Holding SA announces an agreement with the University of Freiburg for the clinical development of Aviptadil in Sarcoidosis
07 October 2017
RELIEF THERAPEUTICS Holding SA announces the exercise of warrants by GEM
07 July 2017
Relief Therapeutics Holding SA announces the resignation of David A. Lowe from his position of member of the Board of Directors
31 May 2017
RELIEF THERAPEUTICS Holding AG (SIX:RLF) announces today the results of its Annual General Meeting 2017 and its Board appointments for 2017
09 May 2017
RELIEF THERAPEUTICS Holding AG (SIX: RLF) publishes the agenda for its 2017 Annual General Meeting
25 October 2016
Relief Therapeutics Holding AG and FirstString Research Inc. announce a strategic collaboration for the development of atexakin alfa
06 October 2016
PX’Therapeutics and RELIEF THERAPEUTICS Holding AG announce a strategic collaboration agreement
28 July 2016
RELIEF THERAPEUTICS Holding AG announces signing of a term sheet to acquire FirstString Research, Inc.
18 July 2016
RELIEF THERAPEUTICS Holding AG announces today the completion of the business combination with Relief Therapeutics SA and the conversion of a CHF 3.3M convertible loan
28 June 2016
THERAMetrics holding AG (SIX:TMX) announces today that it expects to conclude its business combination with Relief Therapeutics SA by mid-July 2016
06 June 2016
THERAMetrics holding AG announces today an agreement to sell its Italian CSS subsidiary
26 May 2016
THERAMetrics holding AG (SIX:TMX) announces today the results of its Annual General Meeting 2016 and its Board appointments for 2016.
Company
Pipeline
Investor Relations
News and Events